A randomized crossover evaluation of antianginal efficacy and safety of nitrolingual-spray and nitroglycerin tablet form in coronary artery disease patients.
Twenty-eight coronary artery disease patients with more than 50% stenosis in at least one major coronary artery completed this randomized crossover clinical trial for the comparison of efficacy and safety of Nitrolingual-Spray and nitroglycerin (NTG) tablets. Exercise time was lengthened to 399.1 s (spray) or 408.5 s (tablets), compared to a baseline of 387.3 s. Ischemic burden decreased to about -4.0 mm with both forms, compared to -7.5 mm at baseline (ANOVA: p = 0.003). The ischemic time improved to 137.2 s (spray) or 152.9 s (tablets), compared to 253.4 s at baseline (ANOVA: p = 0. 005). Patients taking tablets experienced more episodes of hypotension and/or headache compared to patients taking the spray. Nitrolingual-Spray is as effective and safe as NTG tablets for the treatment of symptomatic coronary heart disease.
Chien
K L
KL
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC. klchien@ha.mc.ntu.edu.tw
Sung
F C
FC
Chao
C L
CL
Su
T C
TC
Chen
M F
MF
Lee
Y T
YT
D000280:Administration, Inhalation; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003327:Coronary Disease / Q000188:drug therapy*; D018592:Cross-Over Studies; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D005996:Nitroglycerin / Q000008:administration & dosage*; D012449:Safety; D013607:Tablets; D014665:Vasodilator Agents / Q000008:administration & dosage*
D013607:Tablets; D014665:Vasodilator Agents; D005996:Nitroglycerin